$GH

Eltoukhy Helmy sold $12.6M of GH (indirect holdings)

Eltoukhy Helmy (Co-Chief Executive Officer) sold 100,000 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $126.30 ($125.57–$132.55, $12.63M total) across 7 trades on 2026-06-05.

Original reporting
SEC EDGAR · Eltoukhy Helmy
Published Jun 8, 2026, 10:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

Helmy’s open-market sale reduces insider exposure and can slightly pressure sentiment, but it does not provide new operational/financial information about Guardant Health.

02

Market read

Traders may treat the disclosure as a minor sentiment datapoint rather than a catalyst.

03

What to watch

Check whether other insiders or large holders also sold/bought around the same window; single-officer sales can be idiosyncratic.

Relevance 7/10Novelty 6/10Timing: filed June 8; trades executed June 5

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Guardant Health.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health co-CEO Eltoukhy Helmy sold about $12.63M of GH shares via an open-market sale across 7 trades (Form 4).

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The filing discloses transaction size and timing, but insider sales alone rarely drive sustained repricing without linkage to new company events.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may be planned for liquidity/tax needs; absence of a stated 10b5-1 plan doesn’t automatically imply bearish fundamentals.

Key entities

  • Guardant Health, Inc.

    Company whose shares were sold by an officer/director insider.

  • Eltoukhy Helmy

    Co-Chief Executive Officer and director who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.